Participants who experienced significant nausea, vomiting, or other gastrointestinal symptoms during escalation could have their dose increase paused or delayed until symptoms resolved
Harrison SA, Bashir MR, Guy CD et al (2019) Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial
Advertising Disclosure: This website, along with the products and services mentioned, operates as an advertising marketplace
It is important to note that in UK coding practice, codes from the T36-T50 range are reserved for poisoning (overdose, wrong substance given or taken in error, or wrong route of administration) and should not be used for adverse effects occurring during correct therapeutic use
Willow compounded sublingual tablets use a different formulation, and the bioavailability (how much drug actually enters your bloodstream) may differ from both the injectable and the FDA-approved oral versions